Skip to main content

Clinical Trials Using Etoposide

Review the clinical trials studying etoposide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 91

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Status: Active
Location: 469 locations
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Status: Active
Location: 431 locations
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Status: Active
Location: 339 locations
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Status: Active
Location: 216 locations
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Status: Active
Location: 173 locations
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Status: Active
Location: 179 locations
Dinutuximab with Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children with Newly Diagnosed High Risk Neuroblastoma
Status: Active
Location: 147 locations
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Status: Active
Location: 144 locations
A Study Using Risk Factors to Determine Treatment for Children with Favorable Histology Wilms Tumors (FHWT)
Status: Active
Location: 101 locations
A Study of Lower Radiotherapy Dose to Treat Children with CNS Germinoma
Status: Active
Location: 81 locations
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
Status: Active
Location: 17 locations
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATLL)
Status: Active
Location: 19 locations
Evolutionary Inspired Therapy for the Treatment of Fusion Positive Newly Diagnosed, Metastatic Rhabdomyosarcoma
Status: Active
Location: 15 locations
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
Status: Active
Location: 15 locations
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Status: Active
Location: 10 locations
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Status: Active
Location: 10 locations
Molecular and Clinical Risk Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma
Status: Active
Location: 10 locations
Venetoclax in Combination with Conventional Chemotherapy for the Treatment of Pediatric Patients with Acute Myeloid Leukemia
Status: Active
Location: 9 locations
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Status: Active
Location: 11 locations
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Status: Active
Location: 8 locations
Mogamulizumab with DA-EPOCH for the Treatment of Aggressive T-cell Non-Hodgkin Lymphoma
Status: Active
Location: 8 locations
Second-Line Pembrolizumab in Combination with Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Location: 8 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Status: Active
Location: 8 locations
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
Status: Active
Location: 9 locations
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 7 locations